Report Detail

Pharma & Healthcare Global Targeted Drugs for Breast Cancer

  • RnM3475182
  • |
  • 30 May, 2019
  • |
  • Global
  • |
  • 155 Pages
  • |
  • LPI(LP Information)
  • |
  • Pharma & Healthcare

According to this study, over the next five years the Targeted Drugs for Breast Cancer market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Targeted Drugs for Breast Cancer business, shared in Chapter 3.

This report presents a comprehensive overview, market shares and growth opportunities of Targeted Drugs for Breast Cancer market by product type, application, key companies and key regions.

This study considers the Targeted Drugs for Breast Cancer value generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
HER-2 Targeted Drugs
CDK4/6 Inhibitors
PI3K/AKT/mTor Pathway Inhibitors
ER Targeted Drugs
Aromatase Inhibitors
Tubulin Inhibitors
VEGF Targeted Drugs
YTMS Targeted Drugs
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hospital
Clinic
Drug Center
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Pfizer
Eli Lilly
Novartis
CANbridge
Puma Biotechnology
AstraZeneca
Chugai Pharmaceutical
Eisai
GlaxoSmithKline
Bristol-Myers Squibb
Otsuka Pharmaceutical
Merck
BioMarin
Hengrui Pharmaceutical
Beijing Biostar Technologies
Bayer

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Targeted Drugs for Breast Cancer market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Targeted Drugs for Breast Cancer market by identifying its various subsegments.
Focuses on the key global Targeted Drugs for Breast Cancer players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Targeted Drugs for Breast Cancer with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Targeted Drugs for Breast Cancer submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.


Table of Contents

    2019-2024 Global Targeted Drugs for Breast Cancer Market Report (Status and Outlook)

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global Targeted Drugs for Breast Cancer Market Size 2014-2024
        • 2.1.2 Targeted Drugs for Breast Cancer Market Size CAGR by Region
      • 2.2 Targeted Drugs for Breast Cancer Segment by Type
        • 2.2.1 HER-2 Targeted Drugs
        • 2.2.2 CDK4/6 Inhibitors
        • 2.2.3 PARP Targeted Drugs
        • 2.2.4 PI3K/AKT/mTor Pathway Inhibitors
        • 2.2.5 ER Targeted Drugs
        • 2.2.6 Aromatase Inhibitors
        • 2.2.7 Tubulin Inhibitors
        • 2.2.8 VEGF Targeted Drugs
        • 2.2.9 YTMS Targeted Drugs
        • 2.2.10 Other
      • 2.3 Targeted Drugs for Breast Cancer Market Size by Type
        • 2.3.1 Global Targeted Drugs for Breast Cancer Market Size Market Share by Type (2014-2019)
        • 2.3.2 Global Targeted Drugs for Breast Cancer Market Size Growth Rate by Type (2014-2019)
      • 2.4 Targeted Drugs for Breast Cancer Segment by Application
        • 2.4.1 Hospital
        • 2.4.2 Clinic
        • 2.4.3 Drug Center
        • 2.4.4 Other
      • 2.5 Targeted Drugs for Breast Cancer Market Size by Application
        • 2.5.1 Global Targeted Drugs for Breast Cancer Market Size Market Share by Application (2014-2019)
        • 2.5.2 Global Targeted Drugs for Breast Cancer Market Size Growth Rate by Application (2014-2019)

      3 Global Targeted Drugs for Breast Cancer by Players

      • 3.1 Global Targeted Drugs for Breast Cancer Market Size Market Share by Players
        • 3.1.1 Global Targeted Drugs for Breast Cancer Market Size by Players (2017-2019)
        • 3.1.2 Global Targeted Drugs for Breast Cancer Market Size Market Share by Players (2017-2019)
      • 3.2 Global Targeted Drugs for Breast Cancer Key Players Head office and Products Offered
      • 3.3 Market Concentration Rate Analysis
        • 3.3.1 Competition Landscape Analysis
        • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
      • 3.4 New Products and Potential Entrants
      • 3.5 Mergers & Acquisitions, Expansion

      4 Targeted Drugs for Breast Cancer by Regions

      • 4.1 Targeted Drugs for Breast Cancer Market Size by Regions
      • 4.2 Americas Targeted Drugs for Breast Cancer Market Size Growth
      • 4.3 APAC Targeted Drugs for Breast Cancer Market Size Growth
      • 4.4 Europe Targeted Drugs for Breast Cancer Market Size Growth
      • 4.5 Middle East & Africa Targeted Drugs for Breast Cancer Market Size Growth

      5 Americas

      • 5.1 Americas Targeted Drugs for Breast Cancer Market Size by Countries
      • 5.2 Americas Targeted Drugs for Breast Cancer Market Size by Type
      • 5.3 Americas Targeted Drugs for Breast Cancer Market Size by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC Targeted Drugs for Breast Cancer Market Size by Countries
      • 6.2 APAC Targeted Drugs for Breast Cancer Market Size by Type
      • 6.3 APAC Targeted Drugs for Breast Cancer Market Size by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe Targeted Drugs for Breast Cancer by Countries
      • 7.2 Europe Targeted Drugs for Breast Cancer Market Size by Type
      • 7.3 Europe Targeted Drugs for Breast Cancer Market Size by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa Targeted Drugs for Breast Cancer by Countries
      • 8.2 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Type
      • 8.3 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Global Targeted Drugs for Breast Cancer Market Forecast

      • 10.1 Global Targeted Drugs for Breast Cancer Market Size Forecast (2019-2024)
      • 10.2 Global Targeted Drugs for Breast Cancer Forecast by Regions
        • 10.2.1 Global Targeted Drugs for Breast Cancer Forecast by Regions (2019-2024)
        • 10.2.2 Americas Market Forecast
        • 10.2.3 APAC Market Forecast
        • 10.2.4 Europe Market Forecast
        • 10.2.5 Middle East & Africa Market Forecast
      • 10.3 Americas Forecast by Countries
        • 10.3.1 United States Market Forecast
        • 10.3.2 Canada Market Forecast
        • 10.3.3 Mexico Market Forecast
        • 10.3.4 Brazil Market Forecast
      • 10.4 APAC Forecast by Countries
        • 10.4.1 China Market Forecast
        • 10.4.2 Japan Market Forecast
        • 10.4.3 Korea Market Forecast
        • 10.4.4 Southeast Asia Market Forecast
        • 10.4.5 India Market Forecast
        • 10.4.6 Australia Market Forecast
      • 10.5 Europe Forecast by Countries
        • 10.5.1 Germany Market Forecast
        • 10.5.2 France Market Forecast
        • 10.5.3 UK Market Forecast
        • 10.5.4 Italy Market Forecast
        • 10.5.5 Russia Market Forecast
        • 10.5.6 Spain Market Forecast
      • 10.6 Middle East & Africa Forecast by Countries
        • 10.6.1 Egypt Market Forecast
        • 10.6.2 South Africa Market Forecast
        • 10.6.3 Israel Market Forecast
        • 10.6.4 Turkey Market Forecast
        • 10.6.5 GCC Countries Market Forecast
      • 10.7 Global Targeted Drugs for Breast Cancer Forecast by Type
      • 10.8 Global Targeted Drugs for Breast Cancer Forecast by Application

      11 Key Players Analysis

      • 11.1 Roche
        • 11.1.1 Company Details
        • 11.1.2 Targeted Drugs for Breast Cancer Product Offered
        • 11.1.3 Roche Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
        • 11.1.4 Main Business Overview
        • 11.1.5 Roche News
      • 11.2 Teva
        • 11.2.1 Company Details
        • 11.2.2 Targeted Drugs for Breast Cancer Product Offered
        • 11.2.3 Teva Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
        • 11.2.4 Main Business Overview
        • 11.2.5 Teva News
      • 11.3 Mylan
        • 11.3.1 Company Details
        • 11.3.2 Targeted Drugs for Breast Cancer Product Offered
        • 11.3.3 Mylan Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
        • 11.3.4 Main Business Overview
        • 11.3.5 Mylan News
      • 11.4 Hikma
        • 11.4.1 Company Details
        • 11.4.2 Targeted Drugs for Breast Cancer Product Offered
        • 11.4.3 Hikma Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
        • 11.4.4 Main Business Overview
        • 11.4.5 Hikma News
      • 11.5 Hengrui Medicine
        • 11.5.1 Company Details
        • 11.5.2 Targeted Drugs for Breast Cancer Product Offered
        • 11.5.3 Hengrui Medicine Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
        • 11.5.4 Main Business Overview
        • 11.5.5 Hengrui Medicine News
      • 11.6 Cipla
        • 11.6.1 Company Details
        • 11.6.2 Targeted Drugs for Breast Cancer Product Offered
        • 11.6.3 Cipla Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
        • 11.6.4 Main Business Overview
        • 11.6.5 Cipla News
      • 11.7 Reliance Group
        • 11.7.1 Company Details
        • 11.7.2 Targeted Drugs for Breast Cancer Product Offered
        • 11.7.3 Reliance Group Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
        • 11.7.4 Main Business Overview
        • 11.7.5 Reliance Group News
      • 11.8 Hetero
        • 11.8.1 Company Details
        • 11.8.2 Targeted Drugs for Breast Cancer Product Offered
        • 11.8.3 Hetero Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
        • 11.8.4 Main Business Overview
        • 11.8.5 Hetero News
      • 11.9 Pfizer
        • 11.9.1 Company Details
        • 11.9.2 Targeted Drugs for Breast Cancer Product Offered
        • 11.9.3 Pfizer Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
        • 11.9.4 Main Business Overview
        • 11.9.5 Pfizer News
      • 11.10 Eli Lilly
        • 11.10.1 Company Details
        • 11.10.2 Targeted Drugs for Breast Cancer Product Offered
        • 11.10.3 Eli Lilly Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
        • 11.10.4 Main Business Overview
        • 11.10.5 Eli Lilly News
      • 11.11 Novartis
      • 11.12 CANbridge
      • 11.13 Puma Biotechnology
      • 11.14 AstraZeneca
      • 11.15 Chugai Pharmaceutical
      • 11.16 Eisai
      • 11.17 GlaxoSmithKline
      • 11.18 Bristol-Myers Squibb
      • 11.19 Otsuka Pharmaceutical
      • 11.20 Merck
      • 11.21 BioMarin
      • 11.22 Hengrui Pharmaceutical
      • 11.23 Beijing Biostar Technologies
      • 11.24 Bayer

      12 Research Findings and Conclusion

      Summary:
      Get latest Market Research Reports on Targeted Drugs for Breast Cancer . Industry analysis & Market Report on Targeted Drugs for Breast Cancer is a syndicated market report, published as Global Targeted Drugs for Breast Cancer . It is complete Research Study and Industry Analysis of Targeted Drugs for Breast Cancer market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,660.00
      $5,490.00
      $7,320.00
      2,876.76
      4,315.14
      5,753.52
      3,374.52
      5,061.78
      6,749.04
      575,315.40
      862,973.10
      1,150,630.80
      305,353.80
      458,030.70
      610,707.60
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report